Premium
Dehydroepiandrosterone Augments M1‐Muscarinic Receptor‐Stimulated Amyloid Precursor Protein Secretion in Desensitized PC12M1 Cells
Author(s) -
DANENBERG H. D.,
HARING R.,
HELDMAN E.,
GURWITZ D.,
BENNATHAN D.,
PITTEL Z.,
Zuckerman A.,
FISHER A.
Publication year - 1995
Publication title -
annals of the new york academy of sciences
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.1995.tb17392.x-i1
Subject(s) - dehydroepiandrosterone , endocrinology , medicine , cholinergic , amyloid precursor protein , secretion , carbachol , muscarinic acetylcholine receptor , amyloid (mycology) , alzheimer's disease , receptor , chemistry , biology , androgen , hormone , disease , inorganic chemistry
Epidemiologic studies suggest that the age-related decline in dehydroepiandrosterone (DHEA) levels may be associated with Alzheimer's disease (AD). Cholinergic markers also decline with age, and are associated with AD pathology. Activation of m1AChR-transfected PC12 cells (PC12M1) with cholinergic agonists results in secretion of Alzheimer's beta-amyloid precursor protein (APP) which in turn reduces beta-amyloid production. This study examined whether DHEA affects APP processing in m1AChR-transfected PC12 cells. DHEA treatment did not significantly alter basal or m1AChR-stimulated APP secretion. However, DHEA (0.1 microM) significantly diminished the desensitization of APP secretion in cells exposed to carbachol for 24 h. The effect of DHEA on APP processing is probably not related to up-regulation of m1AChR or increased m1AChR-activated phosphoinositide hydrolysis since these parameters did not change following DHEA treatment. These findings imply a possible involvement of DHEA in APP processing. Thus, the age-associated decline in DHEA levels may contribute to decreased APP secretion and a consecutive increase in beta-amyloid deposition, which in turn may play a role in the development of AD.